Guanze Medical (SEHK:2427) 80.9% Earnings Growth Tests Rich Valuation Narratives

Guanze Medical Information Industry (Holding) (SEHK:2427) has reported its FY 2025 first half results with revenue of C¥31.9 million and basic EPS of C¥0.0036, set against trailing twelve month figures of C¥147.6 million in revenue and C¥0.0222 in EPS that reflect an 80.9% earnings increase over the last year. Over the past three reported half year periods, revenue has moved from C¥40.0 million in 1H 2024 to C¥115.7 million in 2H 2024 and then C¥31.9 million in 1H 2025, while EPS shifted from a small loss of C¥0.0002 to C¥0.0186 and then C¥0.0036. This sets up a results season in which improved profit margins over the last twelve months are a key focus for investors.

See our full analysis for Guanze Medical Information Industry (Holding).

With the headline numbers on the table, the next step is to see how these results line up with the most widely held narratives about Guanze Medical Information Industry (Holding) and where those stories may need to be updated.

Curious how numbers become stories that shape markets? Explore Community Narratives

80.9% earnings swing and a 14% margin

• Over the last 12 months, net income reached C¥20.7 million on revenue of C¥147.6 million, which works out to a 14% net margin compared with 9.4% a year earlier and ties in with the 80.9% year over year earnings increase.
• What stands out for a bullish view is that this 14% margin and C¥20.7 million of trailing net income come after five years where earnings declined on average by 11.3% per year. Recent improvement contrasts with the longer term trend and raises the question of how durable this shift is.
  • Supporters of a bullish angle can point to the move from a small loss in 1H 2024 net income of C¥0.16 million to profits of C¥17.4 million in 2H 2024 and C¥3.4 million in 1H 2025 as evidence that the income line has recently held in positive territory across multiple half years.
  • At the same time, the five year average earnings decline highlights that this recovery sits against a longer history of weaker results, so anyone leaning bullish needs to look closely at what specifically changed in the past year to produce the 80.9% earnings growth.

To see how other investors are weighing that mix of stronger recent margins and a weaker multi year record against their own view of the company, it is worth reading the broader community discussion around Guanze Medical Information Industry (Holding) Curious how numbers become stories that shape markets? Explore Community Narratives.

High P/E of 139.7x versus peers

• The shares trade on a P/E of 139.7x compared with about 13.5x for the Hong Kong healthcare industry and 24.4x for peers, while the current share price of HK$3.47 also sits well above the DCF fair value of HK$0.32. Taken together, this indicates the market is assigning a much richer multiple to these trailing earnings than the sector average.
• Bears focus on this valuation gap and argue that when a stock trades far above a DCF fair value of HK$0.32 and industry level P/E, investors are assuming stronger performance than the recent C¥20.7 million of trailing net income alone would justify.
  • The contrast between a 139.7x P/E and the 13.5x industry average is very large in multiple terms, so even with a 14% net margin, critics see limited room for disappointment before that gap becomes hard to support.
  • High share price volatility over the past three months also fits with a cautious or bearish narrative, since it suggests the market has been quick to reprice the HK$3.47 share price around changes in expectations, not just slow moving fundamentals.

Half year swings behind the full year story

• The last three half year periods show revenue of C¥40.0 million, C¥115.7 million and then C¥31.9 million, alongside net income moving from a small loss of C¥0.16 million to C¥17.4 million and then C¥3.4 million, which helps explain how the trailing 12 month numbers can show stronger profitability even as individual halves vary quite a bit.
• For an investor checking the more cautious arguments, what matters is that this pattern of shifting revenue and net income across 1H 2024, 2H 2024 and 1H 2025 can both support and question a bearish stance that treats recent strength as a one off, because there is at least one half year with C¥17.4 million of net income but also a more modest C¥3.4 million in the latest half.
  • The move from a loss in 1H 2024 to positive net income in the following two halves challenges the idea that the business cannot sustain profitability, even if the size of that profit moves around.
  • At the same time, the lower revenue in 1H 2025 compared with 2H 2024 shows that investors who are cautious have concrete half year figures to point to when they question how smooth the path of future results might be.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Guanze Medical Information Industry (Holding)'s growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If this combination of stronger recent margins and higher valuation multiples leaves you uncertain, act now by reviewing the underlying figures and weighing 1 key reward and 3 important warning signs.

See What Else Is Out There

Guanze Medical Information Industry (Holding) combines a very high 139.7x P/E and DCF value gap with uneven half year earnings, which leaves plenty of room for disappointment.

If that mix of rich pricing and volatile results feels uncomfortable, shift your focus to companies screened as 246 high quality undervalued stocks that may offer more grounded expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com